Clinical Overview of Leber Hereditary Optic Neuropathy.

Q3 Medicine
Acta Medica Lituanica Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI:10.15388/Amed.2022.29.1.19
Almina Stramkauskaitė, Ieva Povilaitytė, Brigita Glebauskienė, Rasa Liutkevičienė
{"title":"Clinical Overview of Leber Hereditary Optic Neuropathy.","authors":"Almina Stramkauskaitė,&nbsp;Ieva Povilaitytė,&nbsp;Brigita Glebauskienė,&nbsp;Rasa Liutkevičienė","doi":"10.15388/Amed.2022.29.1.19","DOIUrl":null,"url":null,"abstract":"<p><p>Leber hereditary ptic neuropathy (LHON) is a disease of young adults with bilateral, painless, subacute visual loss. The peak age of onset of LHON is in the second and third decades of life. Men are 4 times more likely to be affected than women. In about 25-50% of cases, both eyes are affected simultaneously. In unilateral cases, the other eye is usually affected 2 to 3 months later. Visual acuity deteriorates to counting fingers or worse with a dense central or centrocecal scotoma. In the subacute phase, the optic disc may appear hyperemic with swelling of the peripapillary retinal nerve fibre layer, peripapillary telangiectasias, and increased vascular tortuosity. Ocular coherence tomography of the macula shows marked thinning of the ganglion cell complex even at this stage. The diagnosis of LHON is made in a subject with a consistent clinical history and/or one of three common pathogenic mitochondrial DNA (mtDNA) variants identified by molecular genetic testing. Idebenone was approved by the European Medicines Agency under exceptional circumstances for the treatment of LHON. Current evidence suggests some benefit to vision in a subset of affected individuals treated with idebenone, particularly when treated within the first year of onset of vision loss. In this article, we discuss aetiology, clinical features, diagnosis, differential dignosis, prognosis and treatment.</p>","PeriodicalId":34365,"journal":{"name":"Acta Medica Lituanica","volume":"29 1","pages":"9-18"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428633/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Lituanica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15388/Amed.2022.29.1.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

Abstract

Leber hereditary ptic neuropathy (LHON) is a disease of young adults with bilateral, painless, subacute visual loss. The peak age of onset of LHON is in the second and third decades of life. Men are 4 times more likely to be affected than women. In about 25-50% of cases, both eyes are affected simultaneously. In unilateral cases, the other eye is usually affected 2 to 3 months later. Visual acuity deteriorates to counting fingers or worse with a dense central or centrocecal scotoma. In the subacute phase, the optic disc may appear hyperemic with swelling of the peripapillary retinal nerve fibre layer, peripapillary telangiectasias, and increased vascular tortuosity. Ocular coherence tomography of the macula shows marked thinning of the ganglion cell complex even at this stage. The diagnosis of LHON is made in a subject with a consistent clinical history and/or one of three common pathogenic mitochondrial DNA (mtDNA) variants identified by molecular genetic testing. Idebenone was approved by the European Medicines Agency under exceptional circumstances for the treatment of LHON. Current evidence suggests some benefit to vision in a subset of affected individuals treated with idebenone, particularly when treated within the first year of onset of vision loss. In this article, we discuss aetiology, clinical features, diagnosis, differential dignosis, prognosis and treatment.

Abstract Image

Abstract Image

Leber遗传性视神经病变的临床综述。
Leber遗传性视神经病变(LHON)是一种年轻人双侧、无痛、亚急性视力丧失的疾病。LHON发病的高峰年龄是在生命的第二和第三个十年。男性受影响的可能性是女性的4倍。在大约25-50%的病例中,两只眼睛同时受到影响。在单侧病例中,另一只眼睛通常在2至3个月后受到影响。视力恶化到数手指或更糟,有密集的中央或中央暗瘤。在亚急性期,视盘可能出现充血,乳头周围视网膜神经纤维层肿胀,乳头周围毛细血管扩张,血管扭曲增加。黄斑的眼相干断层扫描显示,即使在这个阶段,神经节细胞复合体也明显变薄。LHON的诊断是在具有一致的临床病史和/或通过分子基因检测确定的三种常见致病线粒体DNA (mtDNA)变异之一的受试者中进行的。伊地贝酮在特殊情况下被欧洲药品管理局批准用于治疗LHON。目前的证据表明,使用依地贝酮治疗对一部分受影响个体的视力有一定的好处,特别是在视力丧失发病的第一年内治疗。本文就本病的病因、临床特征、诊断、鉴别诊断、预后及治疗进行讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Medica Lituanica
Acta Medica Lituanica Medicine-General Medicine
CiteScore
0.70
自引率
0.00%
发文量
33
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信